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Background: The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma
(GBM). The O6-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ)
resistance. Our propose is to analyze the prognostic significance of the CD133 antigen and promoter methylation
and protein expression of MGMT in a homogenous group of GBM patients uniformly treated with radiotherapy and
TMZ. The possible connection between these GBM markers was also investigated.
Methods: Seventy-eight patients with GBM treated with radiotherapy combined with concomitant and adjuvant
TMZ were analyzed for MGMT and CD133. MGMT gene promoter methylation was determined by
methylation-specific polymerase chain reaction after bisulfite treatment. MGMT and CD133 expression was assessed
immunohistochemically using an automatic quantification system. Overall and progression-free survival was
calculated according to the Kaplan–Meier method.
Results: The MGMT gene promoter was found to be methylated in 34 patients (44.7%) and unmethylated in 42
patients (55.3%). A significant correlation was observed between MGMT promoter methylation and patients’
survival. Among the unmethylated tumors, 52.4% showed low expression of MGMT and 47.6% showed high-
expression. Among methylated tumors, 58.8% showed low-expression of MGMT and 41.2% showed high-
expression. No correlation was found between MGMT promoter methylation and MGMT expression, or MGMT
expression and survival. In contrast with recent results, CD133 expression was not a predictive marker in GBM
patients. Analyses of possible correlation between CD133 expression and MGMT protein expression or MGMT
promoter methylation were negative.
Conclusions: Our results support the hypothesis that MGMT promoter methylation status but not MGMT
expression may be a predictive biomarker in the treatment of patients with GBM. In addition, CD133 should not be
used for prognostic evaluation of these patients. Future studies will be necessary to determine its clinical utility.
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Glioblastoma (GBM), the most common primary brain
tumor in adults, is a rapidly progressive and fatal disease
with a low median overall survival [1]. The treatment
of these tumors with temozolomide (TMZ) introduces
alkyl groups into DNA preventing its replication.This
structural modification induces cell death. However,
DNA-repair proteins, such as O6-alkylguanine DNA al-
kyltransferase (AGT), are able to remove alkyl adducts
from the O6 position of guanine. Which is especially
harmful, and the O4 position of thymine, restoring these
DNA bases and preventing TMZ-induced cell death [2].
The DNA-repair protein AGT is encoded by the gene O6-
Methlyguanine-DNA-methyltransferase (MGMT). Deter-
mination of promoter methylation of the MGMT gene is
being included as a relevant factor of the patient molecu-
lar profile [3]. Although epigenetic silencing of the
MGMT gene promoter has been associated with pro-
longed survival in glioblastoma patients [4], there is much
controversy about its use as a prognostic marker for the
response of patients with newly diagnosed glioblastoma to
temozolomide [5,6]. Moreover, whether any correlation
exists between MGMT protein expression and promoter
hypermethylation and patient outcomes has not been elu-
cidated. Therefore, various studies using different assess-
ments have reported different results [7-11]. These
inconsistencies may be caused by intratumoral hetero-
geneity, different evaluation methods, and different cut-off
values.
The cancer stem cell (CSC) theory postulates that
tumors arise from a subpopulation of cells that are char-
acterized by self-renewal, infinite proliferative potential,
multipotency, and their ability to initiate new tumors
in vivo [12]. Interestingly, CSC cells are postulated to be
mediators of radio- and chemo-resistance. Tumor cells
with stem-like features have been identified in glioblast-
oma [13]. These cells express the transmembrane glyco-
protein prominin-1 (CD133) (a cell-surface marker
expressed on normal human neuronal stem cell) and
have the ability to initiate a tumor in vivo after xeno-
transplantation in mice. Few data are available on the
actual prognostic impact of CD133 expression in malig-
nant gliomas. Glioblastoma stem cells are highly resis-
tant to conventional chemotherapy and radiotherapy
[14,15] and the chemo-radioresistance of these cells may
be responsible for the poor clinical outcome of these
patients.
The aim of our study is to determine the prognostic
significance of MGMT by analyzing both MGMT gene
promoter methylation and protein expression in a
homogenous series of GBM patients treated with radiothe-
rapy and temozolomide. In addition, we evaluated the
immunohistochemical expression of CD133 investigating
its association with MGMTand clinical outcomes.Methods
Tissue samples
Samples were obtained from the Anatomopathological
Service of Hospital Virgen de las Nieves from Granada
(Spain) and the University Hospital of Sassari (Italy), from
2001 to 2009. The Ethics Committees of both Hospitals
approved the collection and use of human brain tumor tis-
sue samples. We obtained tumor tissue samples from 78
patients with newly diagnosed GBM which was histologi-
cally confirmed and Karnofsky performance score (KPS)
≥ 60. Patients were selected regardless of extent of surgery.
All patients had been treated with concurrent chemo-
radiotherapy (2 Gy per fraction, once a day, five days a
week, 60 Gy total dose) with concomitant TMZ (75 mg
per square meter of body surface area per day for seven
days a week from the first to the last day of radiotherapy)
followed by adjuvant TMZ (200 mg per square meter of
body surface area on days 1 to 5 given at four-weekly inter-
vals). The patient characteristics are summarized in
Table 1.
Patients age 70 years or older with newly diagnosed
GBM and postoperative Karnofsky performance score
(KPS) greater than 60 were eligible for this nonrando-
mized phase II trial
DNA extraction, bisulfite treatment and methylation-
specific PCR
DNA was extracted according to standard protocols.
Methylation patterns in the CpG island of MGMT were
determined by chemical modification of unmethylated, but
not methylated, cytosine to uracil. Methylation-specific
PCR (MSP) was performed with primers specific for either
modified-methylated or unmethylated DNA, as described
previously [16]. DNA (2 μg) was denatured with sodium
hydroxide and modified with sodium bisulfite. DNA sam-
ples were then purified (EpiTect Bisulfite Conversion).
Primer sequences for the unmethylated reaction were
50-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-30 (for-
ward primer) and 50-AACTCCACACTCTTCCAAAAA
CAAAACA-30 (reverse primer), and for the methylated
reaction, they were 50-TTTCGACGTTCTAGGTTTTC
GC-30 (forward primer) and 50-GCACTCTTCCGAAAAC
GAAACG-30 (reverse primer). Amplified products of PCR
were electrophoresed on 3% agarose gels, were visualized
by staining with ethidium bromide, and were examined
under UV illumination.
Immunohistochemistry
Antibodies for MGMT (1:50; Santa Cruz Biotechnology,
Inc.) and CD133 (1:50, Abcam, Cambridge, UK) were used
for immunohistochemical analysis. Immunostaining was
performed using the Bond Polymer Refine Detection sys-
tem (Leica Microsistemas S.L.U, Barcelona, Spain). Briefly,
representative paraffin blocks were cut consecutively at a
Table 1 Patient characteristics (n = 78)
Age (years) Mean 56
Range 24–81
Gender Male 42 (53.8%)
Female 36 (46.1%)




More than one lobe 21 (26.9%)
Duration of symptoms prior
to diagnosis
< 3 months 60 (76.9%)
≥ 3 months 18 (23.1%)
Karnofsky performance score ≥ 60 78 (100%)
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was carried out using the Microprobe Immuno/DNA
stainer (Fisher Scientific, Tustin, CA, USA). Sections were
deparaffinized in xylene and treated with 0.3% hydrogen
peroxide in methanol for 20 min to block endogenous per-
oxidase activity. The sections were washed in phosphate-
buffered saline and then incubated with primary antibodies
for 60 min. The samples were then incubated in secondary
antibody for 8 min. The substrate chromogen, 3.30-diami-
nobenzidine (DAB), enabled visualization of the complex
via a brown precipitate. Hematoxylin (blue) counterstain-
ing enabled the visualization of the cell nuclei. Omission of
primary antibody served as a negative control. Readings
were taken automatically with the ACIS III DAKO system
for quantification immunohistochemistry and were verified
by two experienced pathologist. The percentage of stained
tumor cells was scored as +/− (<10%), 1+ (10% to 25%), 2+
(25% to 50%), 3+ (>50%). For statistical analysis, scores of
+/− and 1+ were defined as low-expression group and
scores of 2+ and 3+ were defined as high-expression.
Statistical analysis
Overall survival (OS) was calculated from the date of the
diagnosis. The progression-free survival (PFS) was calcu-
lated from the date of the progression, according of
MacDonald criteria [17]; size and volume ≥ 25% of initial
measurements, or appearance of a new lesion, or if the
patient’s neurologic condition worsened and required an
increased dose of steroids. The PFS and OS curves were
estimated by the Kaplan-Meier method and compared
using the two-sided log-rank test. A multivariable ana-
lysis was done using the Cox proportional hazards
regression to determine the prognostic effect of vari-
ables. Contingency tables were analyzed by X2 and
Fisher’s exact test. The McNemar test was applied to
compare variables before and after treatment. All calcu-
lations were made using the statistical software SPSS,version 15.0. Statistical significance was set at the level
of P < 0.05.
Results
MGMT promoter methylation status and MGMT protein
expression
The methylation status of the MGMT promoter and
MGMT protein expression was determined for 76 of the
78 tumors (97.4%). Two of the 78 GBM cases were
excluded due to unsuccessful PCR amplification. MGMT
promoter methylation was detected in 44.7% (34/76) of
the GBM samples analyzed by MSP (Figure 1). A positiv-
ity score of 1+, 2+ and 3+ were detected in 31 (40.8%),
19 (25%) and 15 (19.7%) cases respectively (Figure 2).
Only 11 (14.5%) cases showed a score of +/− (Table 2).
For the correlation of MGMT promoter methylation
with MGMT protein expression, the scores +/− and 1+
were categorized into a low-expression group (42,
55.3%), and scores 2+ and 3+ into a high-expression
group (34, 44.7%). Among the 42 unmethylated tumors,
22 (52.4%) showed low-expression of MGMT and 20
(47.6%) showed high-expression while among the 34
methylated tumors, 20 (58.8%) showed low-expression
of MGMT and 14 (41.2%) showed high-expression. No
correlation between MGMT protein expression and
MGMT promoter methylation was observed (P = 0.903).
CD133 protein expression
CD133 expression was available for 75 of the 78 patients
(96.2%). Among the 75 samples, 26 (34.7%), 27 (36%)
and 7 (9.3%) were included as scores 1+, 2+ and 3+
respectively. Fifteen (20%) cases showed a score of +/−
(Figure 3). As was done previously, to correlate MGMT
and CD133 protein expression, the scores were categor-
ized into a low-expression group (41, 54.7%), and a
high-expression group (34, 45.3%) (Table 2). Analysis of
a possible correlation between CD133 expression and
MGMT protein expression or MGMT promoter methy-
lation was negative.
Influence of MGMT promoter methylation status and
MGMT and CD133 protein expression on overall survival
Statistical analysis showed a significant correlation
between OS and MGMT promoter methylation status
(Figure 4A). The median OS among patients with
methylated MGMT promoter tumors was 19 months
(95% CI, 9.6–28.4 months) compared with 13 months
(95% CI, 10.5–15.4 months) in patients with unmethy-
lated MGMT promoter tumors (log-rank, P = 0.031). In
contrast, OS showed no statistically significant diffe-
rences when it was correlated with MGMT expression
(log-rank, P = 0.894) (Figure 4B). The median OS among
patients with high-expression of MGMT was 12 months
(95% CI, 8.8–15.2 months) compared with 13 months
Figure 1 Representative methylation-specific PCR (MSP) analyses of the MGMT promoter in GBM tissue from eleven patients (P). Note
the presence of bands in both the unmethylated (U, 93 bp) and methylated (M, 81 bp) lanes for glioblastoma samples 21, 33 and 40, reflecting a
methylated MGMT promoter. The lack of a band in the lane corresponding to methylation-specific primers for GBM in the rest of the samples
reflects the absence of MGMT promoter methylation. In some samples, such as sample 23, no PCR products were observed (sample excluded).
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tumors (log-rank, P = 0.894). In addition, no differences
were observed between survival estimates of patients
with CD133 low-expression tumors and CD133 high-
expression tumors (Figure 4C). The median OS among pa-
tients with CD133 high-expression tumors was 14 months
(95% CI, 9.1–18.9 months) compared with 13 months
(95% CI, 6.1–19.8 months) in CD133 low-expression
tumors (log-rank, P = 0.787).Influence of MGMT promoter methylation status and
MGMT and CD133 protein expression on progression-free
survival
The median PFS was 8 months (95% CI, 4–12 months) for
the methylated MGMT promoter status compared with
6 months (95% CI, 2.6–9.4 months) for the unmethylated
MGMT promoter status, showing a significant correlation
(log-rank, P = 0.036) (Figure 5A). By contrast, no signifi-
cant correlation was observed between PFS and MGMT
protein expression (Figure 5B). Finally, in these groups,
the median PFS was 7 months (95% CI, 5.2–8.8 months)
for low-CD133 expression tumors compared with 8 months
(95% CI, 6.7–9.3 months) for high-CD133 expression
tumors (P = 0.118) (Figure 5C).Influence of MGMT promoter methylation status and
MGMT and CD133 protein expression on treatment
response
All patients were assessed for clinical and radiological
response. The statistical analysis showed that only the
MGMT promoter status significantly correlated with
radiological response (P = 0.036). The response rate was
significantly higher among patients with a methylated
MGMT promoter status versus an unmethylated status
(43.3% and 17.5%, respectively) (P = 0.036) (Table 3).MGMT promoter methylation and MGMT and CD133
protein expression on recurrent GBM
This study included 11 patients of the 78 patients who
underwent reoperation for tumor recurrence after radio-
chemotherapy. One of the 11 GBM cases was excluded.
In spite of the few samples, there were no significant dif-
ferences between variables before and after treatment
with radiotherapy and temozolomide (McNemar test)
(Table 4).Discussion
Clinical trials have demonstrated a significantly pro-
longed median survival of GBM patients treated with
TMZ associated to radiotherapy after surgical resection
[18-20]. In addition, a strong correlation between the
MGMT gene promoter methylation status and the TMZ
treatment effect and outcome was shown by Hegi et al.
[4], confirming previous results which correlated
MGMT inactivation and clinical response to alkylating
agents [16,21]. Criniere et al. [22] showed that while the
MGMT promoter methylation status had no impact on
the OS of GBM patients treated with alkylating agents, it
did have an impact on those treated with chemo-radio-
therapy, suggesting that the prognostic impact of this
methylation is dependent on therapeutic modalities. In
fact, Weller et al. [23] analyzed patients with GBM trea-
ted with radiotherapy, with chemotherapy and with both
radiotherapy and chemotherapy and showed that the
methylation status was a significant prognostic factor for
OS and PFS only in the subgroup of patients treated
with radiotherapy and concurrent TMZ. These results
have been recently confirmed by Cao et al. [8], Minniti
et al. [24] and Kim et al. [25]. Recently, the methylation
status was analyzed in elderly patients with GBM and
was found to be strictly correlated with the pattern of,
and time until, GBM recurrence [26], but not with its
Figure 2 Representative photomicrographs illustrating different percentages of MGMT-stained tumor cells scored as +/− (A, B, C and
D), 1+ (E), 2+ (F, G, H and I), 3+ (J, K and L) (see Methods) (20×).
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Table 2 Association of MGMT promoter methylation and MGMT and CD133 expression in human GBM
Total Methylated Unmethylated Not done
MGMT expression
Low-expression +/−, + 42 (55.3%) 20 (26.3%) 22 (29%) 2 (2.6%)
High-expression ++, +++ 34 (44.7%) 14 (18.4%) 20 (26.3%)
CD133 expression
Low-expression +/−, + 41 (54.7%) 16 (21.3%) 25 (33.4%) 3 (4%)
High-expression ++, +++ 34 (45.3%) 18 (24%) 16 (21.3%)
Data are represented as the percentage of the total of analyzed patients.
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strated that MGMT promoter methylation was a pre-
dictor of survival in GBM treated exclusively with
radiotherapy. In addition, a randomized phase III trial
comparing standard adjuvant TMZ with a dose-dense
schedule in newly diagnosed GBM confirmed the prog-
nostic significance of MGMT methylation in GBM [29].
However, previous studies considered promoter methy-
lation of the MGMT gene not to be a reliable prognostic
factor of responsiveness to alkylating agents in glioblast-
omas [30]. Recent studies have also questioned the roleFigure 3 Representative photomicrographs illustrating different perc
scored as +/− (A), 1+ (B and C), 2+ (D), 3+ (E) (see methods) (20×).of promoter methylation status of MGMT in GBM.
Yachi et al. [31] failed to establish this correlation in a
larger number of patients and showed that neither MSP-
MGMT methylation nor immunohistochemical MGMT
expression had prognostic implications in GBM patients.
Similarly, Tang et al. [32] did not find a correlation be-
tween progression-free survival and MGMT promoter
methylation in chinese patients. In this context, we con-
ducted a retrospective study in a homogeneous series of
patients diagnosed with GBM treated with radiotherapy
and concurrent temozolomide using MSP, which hasentages of CD133 stained tumor cells corresponding to being
Figure 4 Overall survival curves of patients with GBM
according to MGMT methylation status (A), MGMT expression
(B) and CD133 expression (C).
Figure 5 Progression-free survival curves of patients with GBM
according to MGMT methylation status (A), MGMT expression
(B) and CD133 expression (C).
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Table 3 Radiologic response of GMB patients following
Macdonald et al. [17]
Radiologic response
MGMT Negative Positive
Unmethylated 33 (82.5%) 7 (17.5%)
Methylated 17 (56.7%) 13 (43.3%)
Total 50 (71.4%) 20 (28.6%)
The methylation of MGMT showed a significant correlation with radiologic
response (p < 0.05).
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clinical routine diagnostics [33]. We found that the
percentage of methylation of the MGMT promoter to
be higher than that reported by Hegi et al. [4] but si-
milar to those reported by other authors [22,34]. The
MGMT methylation status was clearly confirmed as an
independent prognostic factor of GBM PFS and OS. In
addition, patients with a methylated MGMT promoter
status had higher response rates to TMZ and radiation
therapy compared to those with a non-methylated sta-
tus, so that MGMT methylation was a predictive factor
for radiologic response
On the other hand, the association between MGMT
protein expression and promoter methylation in vivo has
been widely discussed. Several studies have reported a
significant association of high MGMT expression and
poor prognosis of patients [7-10,35-38]. We analyzed the
expression of MGMT by immunochemistry using a
digital quantitative method to avoid observer variability
[39]. Our study clearly showed no correlation between
MGMT expression and MGMT promoter methylation,
supporting the finding observed by Rodriguez et al. [40]
and Uno et al. [41], or overall survival or radiologicalTable 4 Modulation of MGMT promoter methylation
Patient Pre-treatment Post-treatment
MGMT MGMT CD133 MGMT MGMT CD133
Promoter Promoter
Patient 1 M + ++ M +/− +
Patient 2 M ++ + U ++ +/−
Patient 3 U +++ + U + ++
Patient 4 M ++ + M ++ +
Patient 5 M + ++ U + +
Patient 6 U + + M + +
Patient 7 U + + U + +++
Patient 8 M + ++ U + ++
Patient 9 U +/− + - -
Patient 10 U +/− + U ++ ++
Patient 11 M ++ + M +++ +
MGMT and CD133 in recurrent GBM before and after treatment with
radiotherapy and temozolomide.response coinciding with those findings of Preusser et al.
[11]. The regulation of the MGMT gene is a complex
phenomenon in which promoter hypermethylation is
one of the factors that influence the final expression of
the protein. In this context, the recent demonstration
that there is discordance between MGMT promoter
methylation and levels of MGMT mRNA expression
suggests that other mechanisms may regulate the ex-
pression of this enzyme [42]. It also possibly suggests
that promoter methylation and expression alone are not
sufficient to provide information on the expected clinical
course in patients with malignant glioma who receive
chemotherapy with alkylating agents. In fact, a compre-
hensive study undertaken by sequencing the MGMT
gene promoter has shown a strong correlation between
the methylation site and treatment response [43].
CD133, a five-transmembrane cell surface protein
found in human stem cells from various sources inclu-
ding the central nervous system [44], has been proposed
to detect GBM CSCs. Considering the inherent resist-
ance of CSCs to chemotherapy and radiotherapy [14,15],
it has been hypothesized that the clinical outcome will
be inversely related to the presence of CSC-marker-
positive cells. However, the impact of the presence of
CSC in the clinical progression of tumors is unknown.
Few studies exploring the prognostic value of CD133
expression as a marker of CSC in GBM have been
undertaken; most were heterogeneous and used different
methods (QRT-PCR, immunohistochemistry, FACS) so
that comparisons are difficult. Intense CD133 expression
was detected in high-grade oligodendroglial tumors [45]
and in grade II-IV gliomas [46], both with poor progno-
ses. Similar results were founded in grade IV gliomas
where CD133 expression was related to OS and PFS
[47]. Murat et al. [48] provided evidences that the glio-
blastoma stem cell phenotype (including CD133 expres-
sion) correlated with chemoradiotherapy resistance and
patient survival. In a study with very homogeneous sam-
ples of GBM, high expression of CD133 was found to be
an unfavorable prognostic factor [49]. In addition, an
in vitro study using CSC obtained from 44 GBM
patients to evaluate CD133/Ki67 expression by immuno-
histochemical analysis, concluded that CD133+ was cor-
related to survival [50]. However, the same authors
demonstrated that high expression of CD133 was as-
sociated with a better prognosis when detected by
FASCcan [51]. Similar results were previously found by
Joo et al. [52] who described CD133 as a favourable
prognostic factor for GBM. In this context, our study
clearly demonstrates that CD133 has no implication in
the prognoses of GBM patients supporting similar
results of Kim et al. [53]. Finally, the prognostic impacts
of variations of MGMT promoter methylation or MGMT
and CD133 protein expression after treatment, are
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methylation status has no prognostic value after GBM re-
currence [27]. Our preliminary study in samples obtained
before and after treatment from only ten patients with re-
current GBM suggested that there are no differences be-
tween the analyzed variables although the low number of
patients does not allow to obtain statistically significant
conclusions.Conclusions
Our study was designed to analyze the correlations be-
tween clinical features, MGMT status (promoter methy-
lation and gene expression) and CD133 expression, and
outcome in a set of patients uniformly treated with con-
comitant and adjuvant TMZ and chemo radiation. In
this homogeneous series, the prognostic significance of
MGMT promoter methylation has been clearly demon-
strated. However, MGMT protein expression showed no
correlation with MGMT promoter methylation. In
addition, CD133 expression was correlated neither with
the survival of patients with GBM nor with MGMT. In
light of our data, together with the controversies
reported in the literature, further studies are warranted
to clarify whether MGMT and CD133 can discriminate
between biologically distinct groups of GBM.
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